The Union government has allowed the Serum Institute of India to export 50 lakh doses of COVID-19 vaccine Covishield under the UN-backed COVAX global vaccine programme to Nepal, Tajikistan and Mozambique, official sources said on Sunday.
In addition to these three countries, the SII will also export Covishield to Bangladesh under COVAX, they said.
The SII will commence Covid vaccine export under the COVAX programme from November 23 and Nepal will receive the first lot of Covishield on November 24.
The government, earlier in October, had permitted the SII to export 10 lakh Covishield doses each to Nepal, Myanmar and Bangladesh under the 'Vaccine Maitri' programme.
In a recent communication to the Union Health Ministry, Prakash Kumar Singh, Director, Government and Regulatory Affairs at Serum Institute of India (SII) is learnt to have informed that the Pune-based firm has manufactured stock of 24,89,15,000 doses of Covishield and that the stock is increasing day by day.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)